A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer.
Forty-one patients with advanced colorectal cancer were entered into a randomized controlled trial of treatment with proglumide--a gastrin receptor antagonist. There was no difference in survival between the treated and the untreated groups of patients, although there was a trend towards increased survival in those treated patients with hepatic metastases alone. Proglumide does not cause regression in advanced colorectal cancer but larger studies would be required to detect an effect on tumour growth.
Morris
D L
DL
St. George Hospital, Sydney, Australia.
Charnley
R M
RM
Ballantyne
K C
KC
Jones
J
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000556:secondary; D002272:Carcinoembryonic Antigen / Q000032:analysis; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D009364:Neoplasm Recurrence, Local; D010865:Pilot Projects; D011377:Proglumide / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate
D002272:Carcinoembryonic Antigen; D011377:Proglumide